Palmar-plantar Erythrodysesthesia Syndrome Resulting from Toceranib Phosphate in a Dog with Apocrine Gland Anal Sac Adenocarcinoma: a Case Report

Overview

Journal J Vet Sci

Specialty Veterinary Medicine

Date 2023 Oct 31

PMID 37904638

Authors

Eunjoo Kim

Sung-Soo Kim

Min-Ok Ryu

Affiliations

Soon will be listed here.

Abstract

An 11-year-old neutered male Miniature Poodle with a stage 3 apocrine gland adenocarcinoma was started on chemotherapy with toceranib phosphate after surgery. Beginning on day 10 of toceranib, the dog's foot pads became erythematous and hyperkeratinized. The dog complained of pain, inability to walk, depression, and loss of appetite. The symptoms resolved when toceranib was discontinued and reappeared when toceranib was resumed. Grade 3 palmar-plantar erythrodysesthesia was identified as an adverse event of toceranib based on the VCOG-CTCAE and Naranjo scale. Although very rare in veterinary medicine, clinicians should consider that palmar-plantar erythrodysesthesia can occur after toceranib administration.

References

Lacouture M . Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006; 6(10):803-12. DOI: 10.1038/nrc1970. View

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S . Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer. 2012; 78(1):8-15. DOI: 10.1016/j.lungcan.2012.06.009. View

Liu H, Wu Y, Lv T, Yao Y, Xiao Y, Yuan D . Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2013; 8(1):e55128. PMC: 3559430. DOI: 10.1371/journal.pone.0055128. View

Lacouture M, Anadkat M, Bensadoun R, Bryce J, Chan A, Epstein J . Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011; 19(8):1079-95. PMC: 3128700. DOI: 10.1007/s00520-011-1197-6. View

Chen A, Setser A, Anadkat M, Cotliar J, Olsen E, Garden B . Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol. 2012; 67(5):1025-39. DOI: 10.1016/j.jaad.2012.02.010. View

. Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 2017; 14(4):417-446. DOI: 10.1111/vco.283. View

Cavalcanti J, Hasbach A, Barnes K, Dange R, Patterson J, Saavedra P . Skin depigmentation associated with toceranib phosphate in a dog. Vet Dermatol. 2017; 28(4):400-e95. DOI: 10.1111/vde.12422. View

Feo Bernabe L, Portela R, Nguyen S, Kisseberth W, Pennell M, Yancey M . Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. BMC Vet Res. 2013; 9:190. PMC: 3850926. DOI: 10.1186/1746-6148-9-190. View

10.

Polton G, Brearley M . Clinical stage, therapy, and prognosis in canine anal sac gland carcinoma. J Vet Intern Med. 2007; 21(2):274-80. DOI: 10.1892/0891-6640(2007)21[274:cstapi]2.0.co;2. View

11.

Heaton C, Fernandes A, Jark P, Pan X . Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs. J Vet Intern Med. 2020; 34(2):873-881. PMC: 7096647. DOI: 10.1111/jvim.15706. View

12.

Tseng L, Chen K, Wang C, Weng L . Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study. Medicine (Baltimore). 2020; 99(23):e20510. PMC: 7306373. DOI: 10.1097/MD.0000000000020510. View

13.

Nikolaou V, Syrigos K, Saif M . Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf. 2016; 15(12):1625-1633. DOI: 10.1080/14740338.2016.1238067. View

14.

Terada T, Noda S, Inui K . Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther. 2015; 152:125-34. DOI: 10.1016/j.pharmthera.2015.05.009. View

15.

Lipworth A, Robert C, Zhu A . Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009; 77(5):257-71. DOI: 10.1159/000258880. View

16.

Elliott J . Response and outcome following toceranib phosphate treatment for stage four anal sac apocrine gland adenocarcinoma in dogs: 15 cases (2013-2017). J Am Vet Med Assoc. 2019; 254(8):960-966. DOI: 10.2460/javma.254.8.960. View

17.

Califano R, Tariq N, Compton S, Fitzgerald D, Harwood C, Lal R . Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. Drugs. 2015; 75(12):1335-48. PMC: 4532717. DOI: 10.1007/s40265-015-0434-6. View